Mortality Following Treatment With and Without Paclitaxel-Coated Devices in Dialysis Patients

Abstract

Objectives:

To evaluate the mortality after treatment with a paclitaxel (PTX)-coated device and with uncoated devices of iliac, femoropopliteal, and below-the-knee lesions in dialysis patients.

Methods:

Retrospective mortality analysis of dialysis patients with peripheral artery disease who underwent treatment of iliac, femoropopliteal, and/or infrapopliteal lesions with PTX-coated or uncoated devices.

Results:

Between 2010 and 2018, 1125 dialysis patients were treated with iliac and/or femoropopliteal and/or infrapopliteal lesions. In all, 359 patients were selected for this retrospective analysis. Of those, 122 patients were treated with uncoated devices without crossover to a PTX-coated device during follow-up and 237 patients were treated with a PTX-coated device. Mean follow-up time was 27.38±24.76 months (range=0–103). For the entire cohort, the overall mortality was 95.1% after uncoated treatment and 75.9% after PTX treatment (p<0.001). After propensity score matching (n=119), overall mortality was 95.0% after uncoated treatment and 78.2% after PTX treatment (p<0.001). For the entire cohort, multivariate logistic regression analysis revealed age (p=0.002) and critical limb ischemia (p<0.001) as independent predictors for mortality. PTX treatment was a protective factor for mortality (p<0.001).

Conclusion:

Mortality in dialysis patients is in general high and higher after use of uncoated devices compared with PTX-coated devices. Mortality predictors were risk factors and disease severity but not PTX treatment.

Clinical Impact

After the publication of Katsanos’s metaanalyses, the uncertainty regarding PTX device safety in peripheral interventions in patients mainly without end-stage renal insufficiency was initially considerable. The present study for the first time investigates the potential long-term mortality risk of dialysis patients following PTX device treatment of PAD. In contrast to a recent meta-analysis, this real-world study could show a better survival after PTX treatment in comparison to uncoated devices.

Keywords

peripheral arterial occlusive disease angioplasty mortality paclitaxel

Get full access to this article

View all access options for this article.

References

O’Hare

Johansen

KL.

Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12:2838–2847.

Graziani

Silvestro

Bertone

, et al. Percutaneous transluminal angioplasty is feasible and effective in patients on chronic dialysis with severe peripheral artery disease. Nephrol Dial Transplant. 2007;22(4):1144–1149.

Kumada

Aoyama

Ishii

, et al. Long-term outcome of percutaneous transluminal angioplasty in chronic haemodialysis patients with peripheral arterial disease. Nephrol Dial Transplant. 2008;23(12):3996–4001.

Reinecke

Unrath

Freisinger

, et al. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart J. 2015;36:932–938.

Cambou

Aboyans

Constans

, et al. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry. Eur J Vasc Endovasc Surg. 2010;39(5):577–585.

Norgren

Hiatt

Dormandy

, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:S5–S67.

Lawall

Huppert

Rümenapf

S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. 2015.

Dake

Ansel

Jaff

, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.

Tepe

Zeller

Albrecht

, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–699.

10.

Werk

Langner

Reinkensmeier

, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–1365.

11.

Fanelli

Cannavale

Boatta

, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther. 2012;19(5):571–580.

12.

Liistro

Porto

Angioli

, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615–621.

13.

Zeller

Baumgartner

Scheinert

, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568–1576.

14.

Zeller

Beschorner

Pilger

, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK’S-first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015;8(12):1614–1622.

15.

Katsanos

Spiliopoulos

Kitrou

, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.

16.

Katsanos

Spiliopoulos

Kitrou

, et al. Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials. J Vasc Interv Radiol. 2020;31:202–212.

17.

FDA, US. ELUVIA drug-eluting vascular stent system. 2018. https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180011B.pdf. Accessed May 7.

18.

FDA, US. IN.PACT admiral paclitaxel-coated PTA balloon catheter summary of safety and effectiveness data. 2014. https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140010B.pdf. Accessed May 7.

19.

FDA, US. LUTONIX 035 drug coated balloon PTA catheter (AVF indiction) summary of safety and effectiveness data. 2017. https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130024S009B.pdf. Accessed May 7.

20.

FDA, US. Stellarex 0.035” OTW drug-cated angioplasty balloon summary of safety and effectiveness data. 2017. https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160049B.pdf. Accessed May 7.

21.

Cook Medical, Zilver®PTX®. Drug-eluting peripheral stent, instructions for Ise, IFU 0118-6. https://www.cookmedical.com/products/224e3666-308f-4244-8695-6fd23bbd671c/

22.

Freisinger

Koeppe

Gerss

, et al. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. Eur Heart J. 2020;41:3732–3739.

23.

Secemsky

Kundi

Weinberg

, et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019;4:332–340.

24.

Böhme

Noory

Beschorner

, et al. Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in the real world. JACC Cardiovasc Interv. 2020;13:2052–2061.

25.

Monsarrat

Royer

Wright

, et al. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Bull Cancer. 1997;84(2):125–133.

26.

Kennedy

Mafeld

Baerlocher

, et al. Drug-coated balloon angioplasty in hemodialysis circuits: a systematic review and meta-analysis. J Vasc Interv Radiol. 2019;30(4):483–494.

27.

Cao

Zhang

, et al. Comparative effectiveness of drug-coated balloon vs balloon angioplasty for the treatment of arteriovenous fistula stenosis: a meta-analysis. J Endovasc Ther. 2020;27(2):266–275.

28.

Trerotola

Saad

Roy-Chaudhury

, et al. The Lutonix AV randomized trial of paclitaxel-coated balloons in arteriovenous fistula stenosis: 2-year results and subgroup analysis. J Vasc Interv Radiol. 2020;31(1):1–14.

29.

Lookstein

Haruguchi

Ouriel

, et al. Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas. N Engl J Med. 2020;383:733–742.

30.

United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020.

31.

Trerotola

Lawson

Roy-Chaudhury

, et al. Drug coated balloon angioplasty in failing AV fistulas: a randomized controlled trial. Clin J Am Soc of Nephrol. 2018;13:1215–1224.

32.

Takeji

Yamaji

Tomoi

, et al. Impact of frailty on clinical outcomes in patients with critical limb ischemia. Circ Cardiovasc Interv. 2018;11(7):e006778.

33.

Yang

Ning

Shang

, et al. Association of peripheral arterial disease with all-cause and cardiovascular mortality in hemodialysis patients: a meta-analysis. BMC Nephrol. 2016;17:1–9.

34.

Otsubo

Kitamura

Wakaume

, et al. Association of peripheral artery disease and long-term mortality in hemodialysis patients. Int Urol Nephrol. 2012;44(2):569–573.

35.

Rollins

Jackson

Coughlin

PA.

Meta-analysis of contemporary short-and long-term mortality rates in patients diagnosed with critical leg ischaemia. Br J Surg. 2013;100(8):1002–1008.

36.

Taylor

Cull

Kalbaugh

, et al. Comparison of interventional outcomes according to preoperative indication: a single center analysis of 2,240 limb revascularizations. J Am Coll Surg. 2009;208(5):770–778; discussion 778.

37.

Schneider

Laird

Doros

, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73:2550–2563.

38.

Böhme

Noory

Beschorner

, et al. Mortality following treatment with paclitaxel-coated devices in real world utilization: correlation to total lifetime dosage? J Vasc Interv Radiol. 2021;32(12):1671–1678.

39.

Tallarida

Jacobs

. The Dose-Response Relation in Pharmacology. New York: Springer; 1979:1–17.